The company also provided updates on the front-line development strategies for its parallel lead programs in both ROS1-positive and ALK-positive NSCLC. For zidesamtinib, Nuvalent has aligned with ...

A new stretch of border wall will soon be built through the San Rafael Valley, southeast Arizona's last major open space for cross-border wildlife migration, and a place where humans ...

The NCCN has added taletrectinib to its recommendations for use in all lines of treatments for non–small cell lung cancer harboring ROS1 mutations.